1.Lumley J, Watson L, Watson M & Bower C (2001) Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev issue 3, CD001056.
2.European Surveillance of Congenital Anomalies (2005) Special Report: Prevention of Neural Tube Defects by Perioconceptional Folic Acid Supplementation in Europe. Northern Ireland: Eurocat.
3.Lancaster P & Hurst T (2001) Trends in Neural Tube Defects in Australia. Canberra: AIHW National Perinatal Statistics Unit, University of New South Wales, Australian Food and Nutrition Monitoring Unit.
4.Bower C, DeKlerk N, Hickling S, Ambrosini G, Flicker L, Geelhoed E & Milne E (2006) Assessment of the potential effect of incremental increases on folic acid intake on neural tube defects in Australia and New Zealand. Aust N Z J Public Health 30, 369–374.
5.Department of Health (1992) Folic Acid and the Prevention of Neural Tube Defects. Report from an Expert Advisory Group. London: HMSO.
6.Institute of Medicine, Food and Nutrition Board (1998) Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press.
7.Australian Government, Department of Health and Ageing, National Health and Medical Research Council & New Zealand Ministry of Health (2006) Nutrient Reference Values for Australia and New Zealand Including Recommended Dietary Intakes. Canberra: Commonwealth of Australia.
8.Conlin ML, MacLennan AH & Broadbent JL (2006) Inadequate compliance with periconceptional folic acid supplementation in South Australia. Aust N Z J Obstet Gynaecol 46, 528–533.
10.Bower C, Ryan A, Rudy E & Miller M (2002) Trends in neural tube defects in Western Australia. Aust N Z J Public Health 26, 150–151.
11.Food Standards Australia and New Zealand (2006) Final Assessment Report. Proposal P295. Consideration of Mandatory Fortification with Folic Acid. Canberra: FSANZ.
12.Australian Bureau of Statistics (1998) National Nutrition Survey: Nutrient Intakes and Physical Measurements. Australia, 1995. ABS Catalogue no. 4805.0. Canberra: ABS.
13.New Zealand Ministry of Health (1999) NZ Food: NZ People – Key Results of the 1997 National Nutrition Survey. Wellington: NZMoH.
14.Bower C, Blum L, O’Daly K, Higgins C, Loutsky F & Kosky C (1997) Promotion of folate for the prevention of neural tube defects: knowledge and use of periconceptional folic acid supplements in Western Australia, 1992 to 1995. Aust N Z J Public Health 21, 716–721.
15.Centre for Reviews and Dissemination (2001) Undertaking Systematic Reviews of Research on Effectiveness: CRD’s Guidance for Those Carrying Out or Commissioning Reviews. CRD Report no. 4, 2nd ed. York: University of York.
16.Austral ian Government, Department of Health and Ageing (2006) Medicare Benefits Schedule Book. Canberra: Commonwealth of Australia.
17.Carter R & Scollo M (2000) Economic evaluation of the National Tobacco Campaign. In Australia’s National Tobacco Campaign: Evaluation Report. vol. 2: Every Cigarette Is Doing You Damage, pp. 201–244 [K Hassard, editor]. Canberra: Commonwealth Department of Health and Ageing.
20.Cameron M, Haworth N, Oxley J, Newstead S & Le T (1993) Evaluation of Transport Accident Commission Road Safety Television Advertising. MUARC Report no. 52. Victoria: Monash University Accident Research Centre.
21.Rapley M (2003) QoL in health and social care. In Quality of Life Research: A Critical Introduction, Ist ed., pp. 139–165. London: Sage Publications.
22.Stouthard MEA, Essink-Bot M-L & Bonsel GJ, on behalf of the Dutch Disability Weights Group (2000) Disability weights for diseases: a modified protocol and results for a Western European region. Eur J Public Health 10, 24–30.
23.Department of Human Services, Public Health Division (1999) Victorian Burden of Disease Study: Morbidity. Melbourne: Department of Human Services.
24.Access Economics (2006) Cost benefit analysis of fortifying the food supply with folic acid. In Final Assessment Report. Proposal P295. Consideration of Mandatory Fortification with Folic Acid, pp. 20–21, attachment 11b. Canberra: FSANZ.
25.Australian Bureau of Statistics (2006) Population by Age and Sex, Australian States and Territories. ABS Catalogue no. 3201.0. Canberra: ABS.
26.Rowland CA, Correa A, Cragan JD & Alverson CJ (2006) Are encephaloceles neural tube defects? Pediatrics 118, 916–923.
27.George B, Harris A & Mitchell A (2001) Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19, 1–8.
28.Busby A, Abramsky L, Dolk H & Armstrong BA (2005) Eurocat Folic Acid Working Group. Preventing neural tube defects in Europe: population based study. BMJ 330, 574–575.
29.Centers for Disease Control and Prevention (2008) Use of supplements containing folic acid among women of childbearing age – United States, 2007. MMWR Morb Mortal Wkly Rep 57, 5–8.
30.Lawrence JM, Watkins ML, Chiu V, Erikson JD & Petitti DB (2006) Do racial and ethnic differences in serum folate values exist after food fortification with folic acid? Am J Obstet Gynecol 194, 520–526.
31.Centers for Disease Control and Prevention (2008) Treated in wheat-flour fortification with folic acid and iron – worldwide, 2004 and 2007. MMWR Morb Mortal Wkly Rep 57, 8–10.
32.Choumenkovitch SF, Selhub J, Wilson PWF, Rader JI, Rosenberg IH & Jacques PF (2002) Folic acid intake from fortification in the United States exceeds predictions. J Nutr 132, 2792–2798.
33.Centers for Disease Control and Prevention (2004) Spina bifida and anencephaly before and after folic acid mandate – United States, 1995–1996 and 1999–2000. MMWR Morb Moral Wkly Rep 53, 362–365.
34.Grosse SD, Waitzman NJ, Romano PS & Mulinare J (2005) Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation and public health. Am J Public Health 95, 1917–1922.
35.Pfeiffer CM, Johnson CL, Jain RB, Yetley EA, Picciano MF, Rader JI, Fisher KD, Mulinare J & Osterloh JD (2007) Trends in blood folate and vitamin B-12 concentrations in the United States, 1988–2004. Am J Clin Nutr 86, 718–721.
36.De Wals P, Tairou F, Van Allen MI et al. (2007) Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 357, 135–142.
37.Lopez-Camelo JS, Orioli IM, da Graca Dutra M et al. (2005) Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet A 135, 120–125.
38.Chen LT & Rivera MA (2004) The Costa Rican experience: reduction in neural tube defects following food fortification programs. Nutr Rev 62, 6 Pt 2, S40–S43.
39.Safdar OY, Al-Dabbagh AA, Abueliieneen WA & Kari JA (2007) Decline in incidence of neural tube defects after the national fortification of flour (1997–2005). Saudi Med J 28, 1227–1229.
40.Daly LE, Kirke PN, Molloy A, Weir DG & Scott JM (2005) Folate levels and neural tube defects: implications for prevention. JAMA 274, 1698–1702.
41.Dietrich M, Brown CJP & Block G (2005) The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr 24, 266–274.
42.Llanos A, Hertrampf E, Cortes F, Pardo A, Grosse SD & Uauy R (2007) Cost-effectiveness of a folic acid fortification program in Chile. Health Policy 83, 295–303.
43.Jentik J, can de Vrie-Hoekstra NW, de Jong-van den Berg LT & Postma MJ (2008) Economic evaluation of folic acid food fortification in The Netherlands. Eur J Public Health 18, 270–274.
44.Romano PS, Waitzman NJ, Scheffler RM & Pi RD (1995) Folic acid fortification of grain: an economic analysis. Am J Public Health 85, 667–676.
45.Postma MJ, Londeman J, Veenstra M, de Walle HEK & de Jong- van den Berg LTW (2002) Cost effectiveness of periconceptional supplementation of folic acid. PharmWorld Sci 24, 8–11.
46.Fenech M, Noakes M, Clifton P & Topping D (1999) Aleurone flour is a rich source of bioavailable folate in humans. J Nutr 129, 1114–1119.
47.Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunick MG, Goldman PA, Williams L & Goldman L (2001) Cost effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 286, 936–943.
48.Hutubessy R, Chisholm D, Tan-Torres Edejer T & WHO-CHOICE (2003) Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1, 1–13.
49.Murray CJL, Evans DB, Acharya A & Baltussen RMPM (2000) Development of the WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9, 235–251.
50.Marsack CR, Alsop CL, Kurinczuk JJ & Bower C (1995) Pre-pregnancy counselling for the primary prevention of birth defects: rubella vaccination and folate intake. Med J Aust 162, 403–406.
51.Chacko MR, Anding R, Kozinetz CA, Grover JL & Smith PB (2003) Neural tube defects: knowledge and preconceptional prevention practices in minority young women. Pediatrics 112, 536–542.
52.Robbins JM, Cleves MA, Collins HB, Andrews N, Smith LN & Hobbs CA (2005) Randomized trial of a physician-based intervention to increase the use of folic acid supplements among women. Am J Obstet Gynecol 192, 1126–1132.
53.Ashfield-Watt PAL, Whiting JM, Clark ZE, Moat SJ, Newcombe RG, Burr ML & McDowell IFW (2003) A comparison of the effect of advice to eat either ‘5-a-day’ fruit and vegetables or folic acid-fortified foods on plasma folate and homocysteine. Eur J Clin Nutr 57, 316–323.
54.Woolcott Research (2006) Research Report: Evaluation of the National Go For 2&5 Campaign. New South Wales: Woolcott Research.
55.de Walle HEK, van der Pal KM, de Jong-van den Berg LTW, Jeeninga W, Schouten JSAG, de Rover CM, Buitendijk SE & Cornel MC (1999) Effect of mass media campaign to reduce socioeconomic differences in women’s awareness and behaviour concerning use of folic acid: cross sectional study. BMJ 319, 291–292.